← Back to Search

Polyphenol

Curcumin for Chronic Kidney Disease

Phase 2
Waitlist Available
Research Sponsored by Diana Jalal
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Study Summary

This trial will test whether curcumin can improve vascular function and cognitive function in patients with CKD by reducing oxidative stress and inflammation.

Who is the study for?
This trial is for adults who can consent, have moderate to severe chronic kidney disease (not the most advanced stages), and a BMI under 35. It's not for those who've eaten lots of curcumin or taken supplements recently, are pregnant or not using birth control, have very serious heart failure, recent hospital stays, current infections or recent heavy-duty immune system drugs.Check my eligibility
What is being tested?
The study tests if curcumin improves blood vessel function and reduces stiffness in arteries by tackling oxidative stress in patients with chronic kidney disease. It also looks at whether curcumin helps with brain functions like memory and thinking. Participants will either receive curcumin or a placebo without active ingredients.See study design
What are the potential side effects?
Curcumin is generally considered safe but may cause digestive upset like gas, bloating, diarrhea; yellow stool; headaches; rashes; and low blood sugar levels especially in people with diabetes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Vascular endothelial function
Secondary outcome measures
Cognition
Large artery stiffness

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CurcuminExperimental Treatment1 Intervention
Patients will receive curcumin (Lonvida) 2000 mg PO once a day
Group II: PlaceboPlacebo Group1 Intervention
Patients will receive placebo pill identical in appearance and taste to the supplement
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Curcumin
2017
Completed Phase 4
~1050

Find a Location

Who is running the clinical trial?

Stanford UniversityOTHER
2,406 Previous Clinical Trials
17,343,057 Total Patients Enrolled
University of Colorado, DenverOTHER
1,749 Previous Clinical Trials
2,163,972 Total Patients Enrolled
Diana JalalLead Sponsor
1 Previous Clinical Trials
25 Total Patients Enrolled
~12 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top